ArticleJournal of neurosurgery. Case lessons2025
Leptomeningeal hemangioblastoma: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Oligodendroglioma: An Integrated Diagnostic Approach to CNS Tumors with Oligodendroglioma-like Morphology, with a Focus on Morphological Pitfalls, Immunoprofiles, and Molecular Signatures.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemangioblastoma is a slow-growing vascular tumor commonly found in the posterior fossa. It is associated with von Hippel-Lindau disease, yet most cases arise sporadically. Resection and belzutifan are highly effective in the treatment of hemangioblastoma. Rarely, leptomeningeal dissemination may occur months to years after resection. OBSERVATIONS: A 56-year-old female with cerebellar hemangioblastoma resected in 2016 presented 8 years later with left hemiparesis. Updated neuroimaging revealed new leptomeningeal disease, confirmed via tissue from a right cerebellopontine angle mass. The authors conducted a review of 33 patients diagnosed with leptomeningeal disease; two-thirds were male with a median age of 48 years. Thirty-two patients presented initially with a solitary mass, and 96% of these underwent resection. The mean time from initial lesion resection to dissemination was 94 months. LESSONS: After resection, hemangioblastoma recurrence with leptomeningeal spread is a rare but dangerous possible complication. Management is complex, yet a combination of pan-CNS radiation therapy, targeted resection, and belzutifan (a small-molecule inhibitor that selectively targets and blocks the function of HIF-2α) may represent an effective treatment combination. https://thejns.org/doi/10.3171/CASE25204.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.